Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays

Increasing evidence suggests that some newly emerged SARS-CoV-2 variants of concern (VoCs) resist neutralization by antibodies elicited the early-pandemic wild-type virus. We applied tests to paired recoveree sera (n = 38) using clinical isolates representing first wave (D614G), VoC1, and VoC2 lineages (B.1.1.7 B 1.351). Neutralizing inhibited contemporary VoC1 lineages, whereas inhibition was reduced 8-fold, with 50% failing show neutralization. These results provide for increased potential reinfect previously SARS-CoV-infected individuals. The kinetics NAbs in different patients showed similar decline against all variants, generally low initial anti-B.1.351 responses becoming undetectable, but anti-B.1.1.7 remaining detectable (>20) months after acute infection.